Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, 외. (December 2020). “Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation”. 《Antiviral Research》 184: 104967. doi:10.1016/j.antiviral.2020.104967. PMID33137361.
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). “Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis”. 《Targeted Oncology》 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID28353074. S2CID3833614.
Jain A, Kwong LN, Javle M (November 2016). “Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice”. 《Current Treatment Options in Oncology》 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID27658789. S2CID25477593.
Siddall E, Khatri M, Radhakrishnan J (July 2017). “Capillary leak syndrome: etiologies, pathophysiology, and management”. 《Kidney International》 92 (1): 37–46. doi:10.1016/j.kint.2016.11.029. PMID28318633.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (May 2006). “Cellular pharmacology of gemcitabine”. 《Annals of Oncology》 17 (Suppl 5): v7–12. doi:10.1093/annonc/mdj941. PMID16807468.
Cerqueira NM, Fernandes PA, Ramos MJ (2007). “Understanding ribonucleotide reductase inactivation by gemcitabine”. 《Chemistry: A European Journal》 13 (30): 8507–8515. doi:10.1002/chem.200700260. PMID17636467.
Brown K, Weymouth-Wilson A, Linclau B (April 2015). “A linear synthesis of gemcitabine”. 《Carbohydrate Research》 406: 71–75. doi:10.1016/j.carres.2015.01.001. PMID25681996.
Fatima, M., Iqbal Ahmed, M. M., Batool, F., Riaz, A., Ali, M., Munch-Petersen, B., & Mutahir, Z. (2019). Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 19(4), 342-349. https://doi.org/10.17305/bjbms.2019.4136
World Health Organization (2023). 《The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)》. Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
macmillan.org.uk
“Gemcitabine”. 《Macmillan Cancer Support》. 2017년 3월 25일에 원본 문서에서 보존된 문서. 2017년 5월 6일에 확인함.
medicines.org.uk
“UK label” (영어). UK Electronic Medicines Compendium. 2014년 6월 5일. 2017년 7월 10일에 원본 문서에서 보존된 문서. 2017년 5월 6일에 확인함.
Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, 외. (December 2020). “Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation”. 《Antiviral Research》 184: 104967. doi:10.1016/j.antiviral.2020.104967. PMID33137361.
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). “Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis”. 《Targeted Oncology》 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID28353074. S2CID3833614.
Jain A, Kwong LN, Javle M (November 2016). “Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice”. 《Current Treatment Options in Oncology》 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID27658789. S2CID25477593.
Siddall E, Khatri M, Radhakrishnan J (July 2017). “Capillary leak syndrome: etiologies, pathophysiology, and management”. 《Kidney International》 92 (1): 37–46. doi:10.1016/j.kint.2016.11.029. PMID28318633.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (May 2006). “Cellular pharmacology of gemcitabine”. 《Annals of Oncology》 17 (Suppl 5): v7–12. doi:10.1093/annonc/mdj941. PMID16807468.
Cerqueira NM, Fernandes PA, Ramos MJ (2007). “Understanding ribonucleotide reductase inactivation by gemcitabine”. 《Chemistry: A European Journal》 13 (30): 8507–8515. doi:10.1002/chem.200700260. PMID17636467.
Brown K, Weymouth-Wilson A, Linclau B (April 2015). “A linear synthesis of gemcitabine”. 《Carbohydrate Research》 406: 71–75. doi:10.1016/j.carres.2015.01.001. PMID25681996.
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). “Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis”. 《Targeted Oncology》 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID28353074. S2CID3833614.
Jain A, Kwong LN, Javle M (November 2016). “Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice”. 《Current Treatment Options in Oncology》 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID27658789. S2CID25477593.